arrow
P

Paul Rowland

GlaxoSmithKline
H指数:29
被引数:3,585

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Optimization of Potent and Selective Cyclohexyl Acid ERAP1 Inhibitors Using Structure- and Property-Based Drug Design
2024-11-061
OAAI
Structure-Guided Design and Synthesis of a Pyridazinone Series of Trypanosoma cruzi Proteasome Inhibitors
2023-07-289
OAAI
Investigation of Janus Kinase (JAK) Inhibitors for Lung Delivery and the Importance of Aldehyde Oxidase Metabolism
2021-12-208
PRE
Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode
2021-09-113
PRE
Targeting the Regulatory Site of ER Aminopeptidase 1 Leads to the Discovery of a Natural Product Modulator of Antigen Presentation
2020-02-2830
PREAI
Optimization of Orally Bioavailable PI3Kδ Inhibitors and Identification of Vps34 as a Key Selectivity Target

口服可生物利用的PI3Kδ 抑制剂的优化和Vps34作为关键选择性靶标的鉴定

2019-12-1919
PREAI
Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition
2019-04-08115
OAAI
Isoxazolopyrimidine-Based Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Antimalarial Activity
2018-08-1525
OAAI
Development of a Series of Kynurenine 3-Monooxygenase Inhibitors Leading to a Clinical Candidate for the Treatment of Acute Pancreatitis
2017-04-1125
OAAI
Kynurenine-3-monooxygenase inhibition prevents multiple organ failure in rodent models of acute pancreatitis
2016-01-11132
OAAI
Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease
2015-09-03127
PREAI